LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children.

    Thigpen, James C / Odle, Brian L / Harirforoosh, Sam

    European journal of drug metabolism and pharmacokinetics

    2019  Volume 44, Issue 5, Page(s) 591–609

    Abstract: Pain management in the pediatric population is complex for many reasons. Mild pain is usually managed quite well with oral acetaminophen or ibuprofen. Situations involving more severe pain often require the use of an opioid, which may be administered by ... ...

    Abstract Pain management in the pediatric population is complex for many reasons. Mild pain is usually managed quite well with oral acetaminophen or ibuprofen. Situations involving more severe pain often require the use of an opioid, which may be administered by many different routes, depending on clinical necessity. Acute and chronic disease states, as well as the constantly changing maturational process, produce unique challenges at every level of pediatrics in dosing and management of all medications, especially with regard to high-risk opioids. Although there has been significant progress in the understanding of opioid pharmacokinetics and pharmacodynamics in neonates, infants, children, and adolescents, somewhat limited data exist from which necessary information, concerning the safe and effective use of these agents, may be drawn. The evidence here provided is intended to be helpful in directing the practitioner to patient-specific reasons for preferring one opioid over another. As our knowledge of opioids and their effects has grown, it has become clear that older medications like codeine and meperidine (pethidine) have very limited use in pediatrics. This review provides pharmacokinetic and pharmacodynamic evidence on the currently available opioids: morphine, fentanyl (and derivatives), codeine, meperidine, oxycodone, hydrocodone, hydromorphone, methadone, buprenorphine, butorphanol, nalbuphine, pentazocin, ketobemidone, tramadol, piritramide, naloxone and naltrexone. Morphine, being the most studied opioid analgesic, is the standard against which all others are compared. Pharmacokinetic parameters of morphine that have been found in neonates, i.e., higher volume of distribution, immature metabolic processes that develop at various rates, elimination that is variable based on age and weight, as well as treated and untreated disease processes, are an example of all opioids in the population discussed in this review. Outside the premature and neonatal population, the use of opioids in infants, children, and adolescents quickly begins to resemble the established values found in adults. As such, the concerns (risks) of these medications become comparable to those seen in adults.
    MeSH term(s) Analgesics, Opioid/pharmacokinetics ; Analgesics, Opioid/pharmacology ; Animals ; Child ; Humans ; Infant ; Infant, Newborn ; Pain/drug therapy ; Pain/metabolism ; Pain Management/methods
    Chemical Substances Analgesics, Opioid
    Language English
    Publishing date 2019-04-21
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 196729-0
    ISSN 2107-0180 ; 0398-7639 ; 0378-7966
    ISSN (online) 2107-0180
    ISSN 0398-7639 ; 0378-7966
    DOI 10.1007/s13318-019-00552-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Comparison of pharmacists' scoring of fall risk to other fall risk assessments.

    Panus, Peter C / Covert, Kelly L / Odle, Brian L / Karpen, Samuel C / Walls, Zachary F / Hall, Courtney D

    Journal of the American Pharmacists Association : JAPhA

    2021  Volume 62, Issue 2, Page(s) 505–511.e1

    Abstract: Objectives: Given their professional education and participation within the health care system, pharmacists are ideal candidates to assess drug-associated fall risk for patients. The purpose of this investigation was to determine whether pharmacists can ...

    Abstract Objectives: Given their professional education and participation within the health care system, pharmacists are ideal candidates to assess drug-associated fall risk for patients. The purpose of this investigation was to determine whether pharmacists can quantitatively differentiate individuals who reported falling within the previous year (fallers) from those who do not (nonfallers), and to compare the pharmacists' evaluation with 2 recently published fall risk assessments.
    Design: Cross-sectional design of pharmacists' assessments of fall risk.
    Setting and participants: This is a cross-sectional study where 6 licensed pharmacists evaluated patient records from Wave 1 of the National Social Life, Health and Aging Project dataset using generic drug list (drug counts), age, and body mass index to generate a Pharmacist Risk Score (PRS) based on these variables. Pharmacists were allowed to use drug information resources and were provided with a simple 5-point scale to assist them in scoring patients.
    Outcome measures: The main outcome measure of this study was a comparison of the following fall risk assessments (PRS, drug counts, Medication-Based Index of Physical Function, Quantitative Drug Index, and Timed Up and Go [TUG]) capacity to differentiate fallers from nonfallers.
    Results: Each fall risk assessment was highly correlated (P < 0.001) with the number of reported falls. Drug-associated fall risk assessments were highly correlated (P < 0.001) with each other, but not with TUG. Each fall risk assessment differentiated fallers from nonfallers based on logistic regression (P ≤ 0.001). Receiver operating characteristic (ROC) curve analysis was significant (P ≤ 0.002) for each assessment. The comparison of ROC area under the curve for the fall risk assessments found no significant difference between the PRS and other assessments.
    Conclusion: Fall risk assessment by pharmacists was comparable with other fall risk assessments in distinguishing fallers from nonfallers.
    MeSH term(s) Cross-Sectional Studies ; Humans ; Pharmacists ; Risk Assessment ; Risk Factors
    Language English
    Publishing date 2021-11-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2118585-2
    ISSN 1544-3450 ; 1544-3191 ; 1086-5802
    ISSN (online) 1544-3450
    ISSN 1544-3191 ; 1086-5802
    DOI 10.1016/j.japh.2021.11.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Probable etoposide interaction with Echinacea.

    Bossaer, John B / Odle, Brian L

    Journal of dietary supplements

    2012  Volume 9, Issue 2, Page(s) 90–95

    Abstract: Echinacea is an herbal supplement commonly used as an immune system stimulant to prevent infections, such as the common cold or flu. Echinacea has been documented as a cyctochrome P450 (CYP) 3A4 inhibitor in vitro, but no formal studies have been ... ...

    Abstract Echinacea is an herbal supplement commonly used as an immune system stimulant to prevent infections, such as the common cold or flu. Echinacea has been documented as a cyctochrome P450 (CYP) 3A4 inhibitor in vitro, but no formal studies have been conducted in humans. Etoposide is a cytotoxic, topoisomerase II inhibitor, chemotherapeutic agent used in the treatment of lung cancer. Etoposide is primarily metabolized by CYP 3A4. We report the first possible drug-herbal interaction between Echinacea and etoposide. A 61-year-old gentleman newly diagnosed with nonsmall cell lung cancer began concurrent chemoradiation with cisplatin and etoposide. He was admitted to the hospital on day 8 of his first cycle and found to be thrombocytopenic. His platelet count eventually reached a nadir of 16 × 10(3)/L, requiring platelet transfusion support. Upon admission, it was discovered he was taking Echinacea, which was discontinued. He received his next cycle of chemotherapy without taking Echinacea. His platelet count decreased to a nadir of 44 × 10(3)/L, but he did not require platelet transfusions. Echinacea likely contributed to this patient's profound thrombocytopenia and should be avoided in patients receiving etoposide and possibly other chemotherapeutic drugs that are CYP 3A4 substrates.
    MeSH term(s) Antineoplastic Agents, Phytogenic/pharmacokinetics ; Blood Platelets/metabolism ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/metabolism ; Cytochrome P-450 CYP3A Inhibitors ; Dietary Supplements/adverse effects ; Echinacea ; Etoposide/pharmacokinetics ; Herb-Drug Interactions ; Humans ; Male ; Middle Aged ; Phytotherapy/adverse effects ; Plant Extracts/pharmacology ; Platelet Count ; Thrombocytopenia/blood ; Thrombocytopenia/etiology
    Chemical Substances Antineoplastic Agents, Phytogenic ; Cytochrome P-450 CYP3A Inhibitors ; Plant Extracts ; Etoposide (6PLQ3CP4P3)
    Language English
    Publishing date 2012-06
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2460305-3
    ISSN 1939-022X ; 1939-0211
    ISSN (online) 1939-022X
    ISSN 1939-0211
    DOI 10.3109/19390211.2012.682643
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Influences of Age, Obesity, and Adverse Drug Effects on Balance and Mobility Testing Scores in Ambulatory Older Adults.

    Anson, Eric / Thompson, Elizabeth / Odle, Brian L / Jeka, John / Walls, Zachary F / Panus, Peter C

    Journal of geriatric physical therapy (2001)

    2017  Volume 41, Issue 4, Page(s) 218–229

    Abstract: Background and purpose: The adverse effects of drugs may influence results on tests of mobility and balance, but the drug-specific impact is not identified when using these tests. We propose that a quantitative drug index (QDI) will assist in assessing ... ...

    Abstract Background and purpose: The adverse effects of drugs may influence results on tests of mobility and balance, but the drug-specific impact is not identified when using these tests. We propose that a quantitative drug index (QDI) will assist in assessing fall risk based on these tests, when combined with other fall risk variables.
    Methods: Fifty-seven community-dwelling older adults who could walk independently on a treadmill and had Mini-Mental State Examination (MMSE) scores equal to or greater than 24 participated. Mobility and balance outcome measures included the Balance Evaluation Systems Test (BESTest), Berg Balance Scale (BBS), Timed Up and Go (TUG) and cognitive dual task TUG (TUGc). Fall history, current drug list, and Activity-Specific Balance Confidence (ABC) scale scores were also collected. Body mass index (BMI) was calculated. The QDI was derived from the drug list for each individual, and based on fall-related drug adverse effects. Multiple linear regression analyses were conducted using age, BMI, and QDI as predictor variables for determining mobility and balance test scores, and ABC scale scores. Subsequently, participants were divided into (QDI = 0) low-impact drug group (LIDG) and (QDI > 0) high-impact drug group (HIDG) for Mann-Whitney 2-group comparisons.
    Results: Age, BMI, and QDI were all significant (P < .001) independent variables in multiple regression analyses for mobility and balance test scores, but not for the ABC scale. Separately, the 2 group comparisons for the BESTest, BBS, TUG, and TUGc demonstrated that HIDG scored significantly (P < .05) worse on these tests compared with the LIDG. Drug counts were also significantly higher for the HIDG than for the LIDG. In contrast, age, BMI, MMSE, and reported falls in the last 12 months were not significantly different between groups.
    Conclusion: Age, BMI, and QDI-all contributed independently to the mobility and balance test scores examined, and may provide health care professionals a screening tool to determine whether additional mobility and balance testing is required. In addition, the QDI is a more precise marker of adverse effects of drugs compared with drug counts, as the latter does not quantitate the influence of drugs on physiologic function.
    MeSH term(s) Accidental Falls/prevention & control ; Age Factors ; Aged ; Aged, 80 and over ; Body Mass Index ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Humans ; Linear Models ; Male ; Obesity/epidemiology ; Physical Therapy Modalities/standards ; Postural Balance/physiology ; Range of Motion, Articular ; Walking
    Language English
    Publishing date 2017-05-23
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2250801-6
    ISSN 2152-0895 ; 1539-8412
    ISSN (online) 2152-0895
    ISSN 1539-8412
    DOI 10.1519/JPT.0000000000000124
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Probable Etoposide Interaction with Echinacea

    Bossaer, John B. / Odle, Brian L.

    Journal of dietary supplements

    2012  Volume 9, Issue 2, Page(s) 90

    Language English
    Document type Article
    ZDB-ID 2460305-3
    ISSN 1939-0211
    Database Current Contents Nutrition, Environment, Agriculture

    More links

    Kategorien

  6. Article: Probable Etoposide Interaction with Echinacea

    Bossaer, John B / Odle, Brian L

    Journal of dietary supplements. 2012 May 17, v. 9, no. 2

    2012  

    Abstract: Echinacea is an herbal supplement commonly used as an immune system stimulant to prevent infections, such as the common cold or flu. Echinacea has been documented as a cyctochrome P450 (CYP) 3A4 inhibitor in vitro, but no formal studies have been ... ...

    Abstract Echinacea is an herbal supplement commonly used as an immune system stimulant to prevent infections, such as the common cold or flu. Echinacea has been documented as a cyctochrome P450 (CYP) 3A4 inhibitor in vitro, but no formal studies have been conducted in humans. Etoposide is a cytotoxic, topoisomerase II inhibitor, chemotherapeutic agent used in the treatment of lung cancer. Etoposide is primarily metabolized by CYP 3A4. We report the first possible drug–herbal interaction between Echinacea and etoposide. A 61-year-old gentleman newly diagnosed with nonsmall cell lung cancer began concurrent chemoradiation with cisplatin and etoposide. He was admitted to the hospital on day 8 of his first cycle and found to be thrombocytopenic. His platelet count eventually reached a nadir of 16 × 10³/L, requiring platelet transfusion support. Upon admission, it was discovered he was taking Echinacea, which was discontinued. He received his next cycle of chemotherapy without taking Echinacea. His platelet count decreased to a nadir of 44 × 10³/L, but he did not require platelet transfusions. Echinacea likely contributed to this patient's profound thrombocytopenia and should be avoided in patients receiving etoposide and possibly other chemotherapeutic drugs that are CYP 3A4 substrates.
    Keywords Echinacea ; blood platelet count ; cisplatin ; common cold ; cytotoxicity ; drug therapy ; etoposide ; herbal medicines ; hospitals ; immune system ; influenza ; lung neoplasms ; patients ; thrombocytopenia
    Language English
    Dates of publication 2012-0517
    Size p. 90-95.
    Publishing place Taylor & Francis
    Document type Article
    Note NAL-AP-2-clean
    ZDB-ID 2460305-3
    ISSN 1939-022X ; 1939-0211
    ISSN (online) 1939-022X
    ISSN 1939-0211
    DOI 10.3109/19390211.2012.682643
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  7. Article ; Online: Visual biofeedback training reduces quantitative drugs index scores associated with fall risk.

    Anson, Eric / Thompson, Elizabeth / Karpen, Samuel C / Odle, Brian L / Seier, Edith / Jeka, John / Panus, Peter C

    BMC research notes

    2018  Volume 11, Issue 1, Page(s) 750

    Abstract: Objective: Drugs increase fall risk and decrease performance on balance and mobility tests. Conversely, whether biofeedback training to reduce fall risk also decreases scores on a published drug-based fall risk index has not been documented. Forty-eight ...

    Abstract Objective: Drugs increase fall risk and decrease performance on balance and mobility tests. Conversely, whether biofeedback training to reduce fall risk also decreases scores on a published drug-based fall risk index has not been documented. Forty-eight community-dwelling older adults underwent either treadmill gait training plus visual feedback (+VFB), or walked on a treadmill without feedback. The Quantitative Drug Index (QDI) was derived from each participant's drug list and is based upon all cause drug-associated fall risk. Analysis of covariance assessed changes in the QDI during the study, and data is presented as mean ± standard error of the mean.
    Results: The QDI scores decreased significantly (p = 0.031) for participants receiving treadmill gait training +VFB (- 0.259 ± 0.207), compared to participants who walked on the treadmill without VFB (0.463 ± 0.246). Changes in participants QDI scores were dependent in part upon their age, which was a significant covariate (p = 0.007). These preliminary results demonstrate that rehabilitation to reduce fall risk may also decrease use of drugs associated with falls. Determination of which drugs or drug classes that contribute to the reduction in QDI scores for participants receiving treadmill gait training +VFB, compared to treadmill walking only, will require a larger participant investigation. Trial Registration ISRNCT01690611, ClinicalTrials.gov #366151-1, initial 9/24/2012, completed 4/21/2016.
    MeSH term(s) Accidental Falls/prevention & control ; Aged ; Aged, 80 and over ; Biofeedback, Psychology/methods ; Combined Modality Therapy ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Exercise Therapy/methods ; Humans ; Treatment Outcome
    Language English
    Publishing date 2018-10-22
    Publishing country England
    Document type Clinical Trial ; Journal Article
    ZDB-ID 2413336-X
    ISSN 1756-0500 ; 1756-0500
    ISSN (online) 1756-0500
    ISSN 1756-0500
    DOI 10.1186/s13104-018-3859-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis.

    Lindquist, Desirae E / Stewart, David W / Brewster, Aaryn / Waldroup, Caitlin / Odle, Brian L / Burchette, Jessica E / El-Bazouni, Hadi

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

    2018  Volume 24, Issue 8, Page(s) 1315–1321

    Abstract: Background: Guidelines recommend the use of multiple pharmacologic agents and/or mechanical compressive devices for prevention of venous thromboembolism, but preference for any specific agent is no longer given in regard to safety or efficacy.: ... ...

    Abstract Background: Guidelines recommend the use of multiple pharmacologic agents and/or mechanical compressive devices for prevention of venous thromboembolism, but preference for any specific agent is no longer given in regard to safety or efficacy.
    Objective: To compare postoperative bleeding rates in patients receiving enoxaparin, rivaroxaban, or aspirin for thromboprophylaxis after undergoing elective total hip arthroplasty or total knee arthroplasty.
    Methods: This retrospective cohort analysis evaluated patients who received thromboprophylaxis with either enoxaparin, rivaroxaban, or aspirin. All data were collected from the electronic medical record. The primary outcome was any postoperative bleeding.
    Results: A total of 1244 patients were included with 366 in the aspirin, 438 in the enoxaparin, and 440 in the rivaroxaban arms. Those who received aspirin or enoxaparin were less likely to experience any bleeding compared to those patients who received rivaroxaban ( P < .05). There was also a lower rate of major bleeding in these groups, but the differences were not significant.
    Conclusions: Aspirin and enoxaparin conferred similar bleeding risks, and both exhibited less bleeding than patients who received rivaroxaban.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Arthroplasty, Replacement, Hip/adverse effects ; Arthroplasty, Replacement, Knee/adverse effects ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Blood Loss, Surgical ; Enoxaparin/administration & dosage ; Enoxaparin/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Rivaroxaban/administration & dosage ; Rivaroxaban/adverse effects ; Thrombosis/blood ; Thrombosis/prevention & control
    Chemical Substances Enoxaparin ; Rivaroxaban (9NDF7JZ4M3) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2018-05-01
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 1237357-6
    ISSN 1938-2723 ; 1076-0296
    ISSN (online) 1938-2723
    ISSN 1076-0296
    DOI 10.1177/1076029618772337
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top